Q32 Bio (NASDAQ:QTTB) CFO Lee Kalowski Sells 9,072 Shares of Stock

Q32 Bio Inc. (NASDAQ:QTTB) CFO Lee Kalowski sold 9,072 shares of the company’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $3.46, for a total value of $31,389.12. Following the transaction, the chief financial officer owned 39,938 shares in the company, valued at $138,185.48. This trade represents a 18.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Q32 Bio Price Performance

Shares of QTTB stock traded down $0.09 on Friday, hitting $3.53. The stock had a trading volume of 197,019 shares, compared to its average volume of 1,263,479. The company’s 50 day moving average price is $2.64 and its 200-day moving average price is $2.12. Q32 Bio Inc. has a 1 year low of $1.35 and a 1 year high of $28.06. The firm has a market capitalization of $43.42 million, a P/E ratio of -1.02 and a beta of 0.23.

Q32 Bio (NASDAQ:QTTB) last announced its earnings results on Thursday, November 13th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($1.39) by $0.79. On average, equities analysts forecast that Q32 Bio Inc. will post -12.32 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on QTTB shares. Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a report on Tuesday, October 14th. Wall Street Zen raised shares of Q32 Bio from a “sell” rating to a “hold” rating in a research report on Sunday, October 26th. Two analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $12.17.

Institutional Trading of Q32 Bio

Several hedge funds have recently added to or reduced their stakes in QTTB. Monaco Asset Management SAM lifted its stake in Q32 Bio by 17.1% in the second quarter. Monaco Asset Management SAM now owns 591,937 shares of the company’s stock worth $882,000 after acquiring an additional 86,486 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Q32 Bio in the 1st quarter valued at $92,000. Jane Street Group LLC purchased a new stake in shares of Q32 Bio during the 2nd quarter worth $69,000. AQR Capital Management LLC acquired a new position in shares of Q32 Bio during the first quarter worth $68,000. Finally, Two Sigma Investments LP acquired a new position in shares of Q32 Bio during the third quarter worth $62,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.